
Regina M. Deberry
Examiner (ID: 18586)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647 |
| Total Applications | 1049 |
| Issued Applications | 415 |
| Pending Applications | 152 |
| Abandoned Applications | 510 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19432578
[patent_doc_number] => 20240301076
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => ANTI-CXCR2 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/666190
[patent_app_country] => US
[patent_app_date] => 2024-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18666190
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/666190 | ANTI-CXCR2 ANTIBODIES AND USES THEREOF | May 15, 2024 | Pending |
Array
(
[id] => 19998417
[patent_doc_number] => 20250136639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-01
[patent_title] => Method for purifying PEGylated erythropoietin
[patent_app_type] => utility
[patent_app_number] => 18/645245
[patent_app_country] => US
[patent_app_date] => 2024-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4743
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18645245
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/645245 | Method for purifying PEGylated erythropoietin | Apr 23, 2024 | Pending |
Array
(
[id] => 19830986
[patent_doc_number] => 20250082772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-13
[patent_title] => ANTIBODY-DRUG CONJUGATE
[patent_app_type] => utility
[patent_app_number] => 18/637050
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637050
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637050 | ANTIBODY-DRUG CONJUGATE | Apr 15, 2024 | Pending |
Array
(
[id] => 19345224
[patent_doc_number] => 20240254187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION
[patent_app_type] => utility
[patent_app_number] => 18/624726
[patent_app_country] => US
[patent_app_date] => 2024-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12288
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624726
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/624726 | DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION | Apr 1, 2024 | Abandoned |
Array
(
[id] => 19233782
[patent_doc_number] => 20240190974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => ANTI-ACVR1 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/584551
[patent_app_country] => US
[patent_app_date] => 2024-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584551
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/584551 | ANTI-ACVR1 ANTIBODIES AND USES THEREOF | Feb 21, 2024 | Pending |
Array
(
[id] => 19447361
[patent_doc_number] => 20240307491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION
[patent_app_type] => utility
[patent_app_number] => 18/444110
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444110
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/444110 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION | Feb 15, 2024 | Abandoned |
Array
(
[id] => 19418502
[patent_doc_number] => 20240294625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
[patent_app_type] => utility
[patent_app_number] => 18/401874
[patent_app_country] => US
[patent_app_date] => 2024-01-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 200
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401874
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/401874 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | Jan 1, 2024 | Abandoned |
Array
(
[id] => 19613318
[patent_doc_number] => 20240398998
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/396187
[patent_app_country] => US
[patent_app_date] => 2023-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396187
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/396187 | ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF | Dec 25, 2023 | Issued |
Array
(
[id] => 19127229
[patent_doc_number] => 20240132582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/538465
[patent_app_country] => US
[patent_app_date] => 2023-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40377
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538465
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/538465 | ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF | Dec 12, 2023 | Abandoned |
Array
(
[id] => 19473891
[patent_doc_number] => 12103967
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-01
[patent_title] => Bispecific anti-CCL2 antibodies
[patent_app_type] => utility
[patent_app_number] => 18/509252
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 36
[patent_no_of_words] => 90169
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 283
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509252
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/509252 | Bispecific anti-CCL2 antibodies | Nov 13, 2023 | Issued |
Array
(
[id] => 19265384
[patent_doc_number] => 20240209083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => ANTIBODIES AGAINST TIM3 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/481884
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481884
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/481884 | ANTIBODIES AGAINST TIM3 AND USES THEREOF | Oct 4, 2023 | Abandoned |
Array
(
[id] => 18922985
[patent_doc_number] => 20240025989
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => TREATMENT OF HIDRADENITIS SUPPURATIVA
[patent_app_type] => utility
[patent_app_number] => 18/478374
[patent_app_country] => US
[patent_app_date] => 2023-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6863
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478374
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/478374 | TREATMENT OF HIDRADENITIS SUPPURATIVA | Sep 28, 2023 | Abandoned |
Array
(
[id] => 18921428
[patent_doc_number] => 20240024432
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/464025
[patent_app_country] => US
[patent_app_date] => 2023-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50777
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464025
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/464025 | ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | Sep 7, 2023 | Abandoned |
Array
(
[id] => 19201484
[patent_doc_number] => 20240173383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => COMPOSITIONS COMPRISING RELAXIN AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/215317
[patent_app_country] => US
[patent_app_date] => 2023-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28239
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18215317
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/215317 | COMPOSITIONS COMPRISING RELAXIN AND METHODS OF USE THEREOF | Jun 27, 2023 | Pending |
Array
(
[id] => 19034178
[patent_doc_number] => 20240083993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => BISPECIFIC ANTI-CCL2 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/335941
[patent_app_country] => US
[patent_app_date] => 2023-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 103578
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335941
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/335941 | BISPECIFIC ANTI-CCL2 ANTIBODIES | Jun 14, 2023 | Pending |
Array
(
[id] => 18923016
[patent_doc_number] => 20240026020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ANTI-OPG ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/312897
[patent_app_country] => US
[patent_app_date] => 2023-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312897
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312897 | Anti-OPG antibodies | May 4, 2023 | Issued |
Array
(
[id] => 18923016
[patent_doc_number] => 20240026020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ANTI-OPG ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/312897
[patent_app_country] => US
[patent_app_date] => 2023-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312897
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312897 | Anti-OPG antibodies | May 4, 2023 | Issued |
Array
(
[id] => 18649501
[patent_doc_number] => 20230295317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2
[patent_app_type] => utility
[patent_app_number] => 18/298466
[patent_app_country] => US
[patent_app_date] => 2023-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13010
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18298466
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/298466 | ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2 | Apr 10, 2023 | Pending |
Array
(
[id] => 18739644
[patent_doc_number] => 20230348606
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS
[patent_app_type] => utility
[patent_app_number] => 18/126528
[patent_app_country] => US
[patent_app_date] => 2023-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10986
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18126528
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/126528 | METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS | Mar 26, 2023 | Abandoned |
Array
(
[id] => 18647859
[patent_doc_number] => 20230293635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/156016
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23989
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156016
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156016 | METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE | Jan 17, 2023 | Abandoned |